Similar articles

• Adenosine 3',5'-monophosphate concentrations and responsiveness to thyrotropin and thyroid-stimulating immunoglobulins in normal and Graves' thyroids.

  Kuzuya N, Uchimura H, Ikeda H, Chiu SC, Hamada N, Ito K, Nagataki S. Kuzuya N, et al. J Clin Endocrinol Metab. 1980 Jul;51(1):59-63. doi: 10.1210/jcem-51-1-59. J Clin Endocrinol Metab. 1980. PMID: 6247365 No abstract available.
• Unlike thyrotropin, thyroid-stimulating antibodies do not activate phospholipase C in human thyroid slices.

  Laurent E, Van Sande J, Ludgate M, Corvilain B, Rocmans P, Dumont JE, Mockel J. Laurent E, et al. J Clin Invest. 1991 May;87(5):1634-42. doi: 10.1172/JCI115178. J Clin Invest. 1991. PMID: 1673689 Free PMC article.
• A reconsideration of a thyroid-stimulating immunoglobulin as the cause of hyperthyroidism in Graves' disease.

  McKenzie JM, Zakarija M. McKenzie JM, et al. J Clin Endocrinol Metab. 1976 Apr;42(4):778-81. doi: 10.1210/jcem-42-4-778. J Clin Endocrinol Metab. 1976. PMID: 177449
• The pharmacology of substances affecting the thyroid gland.

  Liberti P, Stanbury JB. Liberti P, et al. Annu Rev Pharmacol. 1971;11:113-42. doi: 10.1146/annurev.pa.11.040171.000553. Annu Rev Pharmacol. 1971. PMID: 4113703 Review. No abstract available.
• Characterization of the thyrotropin receptor and its involvement in Graves' disease.

  Kohn LD. Kohn LD. Horiz Biochem Biophys. 1977;3:123-63. Horiz Biochem Biophys. 1977. PMID: 69601 Review. No abstract available.